ABSTRACT
AIMS: To determine whether low-molecular-weight heparin (LMWH)+glycoprotein (GP) IIb/IIIa inhibitors provide greater benefit than unfractionated heparin (UFH)+GP IIb/IIIa inhibitors, irrespective of renal status. METHODS AND RESULTS: Patients in the Global Registry of Acute Coronary Events (GRACE) were divided into three groups according to creatinine clearance (CrCl): normal renal function (CrCl >60 mL/min), moderate renal dysfunction (30Subject(s)
Anticoagulants/therapeutic use
, Coronary Disease/drug therapy
, Heparin, Low-Molecular-Weight/therapeutic use
, Kidney Diseases/complications
, Platelet Glycoprotein GPIIb-IIIa Complex/therapeutic use
, Acute Disease
, Adolescent
, Adult
, Aged
, Aged, 80 and over
, Coronary Disease/mortality
, Drug Therapy, Combination
, Female
, Hemorrhage/etiology
, Hemorrhage/mortality
, Humans
, Kidney Diseases/mortality
, Male
, Middle Aged
, Prospective Studies
, Statistics as Topic
, Syndrome
, Treatment Outcome
